• Mashup Score: 3

    NewNeuroBytes: Aducanumab for Alzheimer’s DiseaseQuestions about the NeuroBytes Program?Email OnlineLearningCenter@aan.com. Or Contact Member Services:Email MemberServices@aan.com. Call (800) 879-1960 or (612) 928-6000 (International).View DetailsBuy NowNewNeuroBytes: CGRP in the Treatment and Prevention of MigraineQuestions about the NeuroBytes Program?Email OnlineLearningCenter@aan.com. Or…

    Tweet Tweets with this article
    • This NeuroBytes provides an overview of this class of medications, including dosing and use in both prevention and acute migraine treatment. https://t.co/RLqIGDkB7I #Neurology #NeuroTwitter #MigraineTreatment @LCharlestonIVMD https://t.co/gBi8aGQj46

  • Mashup Score: 0

    The FDA approved dihydroergotamine mesylate for the treatment of adults with acute migraine with or without aura, according to a press release from the drug’s manufacturer. Dihydroergotamine mesylate (Trudhesa, Impel NeuroPharma) is a nasal spray that, via a Precision Olfactory Delivery system, provides 0.725 mg of the medication with each spray.

    Tweet Tweets with this article
    • The @FDA approves a DHE-based #migrainetreatment called #Trudhesa https://t.co/FVM1NMSZdg

  • Mashup Score: 6

    The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers including neurologists, primary care physicians and advanced practice providers.

    Tweet Tweets with this article
    • Register for our virtual #NextGeneration Migraine program. If you'd like to talk with experts, you can register for the Q&A session, Feb 20, moderated by AHS President Peter Goadsby, MD, PhD, FAHS. #MigraineTreatment https://t.co/aA6OzRDVgV https://t.co/Y46npQeGBa